98%
921
2 minutes
20
Introduction: Prostate bed radiotherapy (RT) is a major affecter of patients' long-term quality of life (QoL). To ensure the best possible outcome of these patients, dose constraints are key for optimal RT planning and delivery. However, establishing refined dose constraints requires access to patient-level data. Therefore, we aimed to provide such data on the relationship between OAR and gastrointestinal (GI) as well as genitourinary (GU) QoL outcomes of a homogenous patient cohort who received dose-intensified post-operative RT to the prostate bed. Furthermore, we aimed to conduct an exploratory analysis of the resulting data.
Methods: Patients who were treated with prostate bed RT between 2010 and 2020 were inquired about their QoL based on the Expanded Prostate Cancer Index Composite (EPIC). Those (n = 99) who received volumetric arc therapy (VMAT) of at least 70 Gy to the prostate bed were included. Dose-volume histogram (DVH) parameters were gathered and correlated with the EPIC scores.
Results: The median age at the time of prostate bed RT was 68.9 years, and patients were inquired about their QoL in the median 2.3 years after RT. The median pre-RT prostate-specific antigen (PSA) serum level was 0.35 ng/mL. The median duration between surgery and RT was 1.5 years. The median prescribed dose to the prostate bed was 72 Gy. A total of 61.6% received prostate bed RT only. For the bladder, the highest level of statistical correlation ( < 0.01) was seen for V10-20Gy, Dmean and Dmedian with urinary QoL. For bladder wall, the highest level of statistically significant correlation ( < 0.01) was seen for V5-25Gy, Dmean and Dmedian with urinary QoL. Penile bulb V70Gy was statistically significantly correlated with sexual QoL ( < 0.05). A larger rectal volume was significantly correlated with improved bowel QoL ( < 0.05). Sigmoid and urethral DVH parameters as well as the surgical approach were not statistically significantly correlated with QoL.
Conclusion: Specific dose constraints for bladder volumes receiving low doses seem desirable for the further optimization of prostate bed RT. This may be particularly relevant in the context of the aspiration of establishing focal RT of prostate cancer and its local recurrences. Our comprehensive dataset may aid future researchers in achieving these goals.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340614 | PMC |
http://dx.doi.org/10.3390/cancers15133454 | DOI Listing |
Pract Radiat Oncol
September 2025
Department of Radiation Oncology, Institut Bergonié, Bordeaux, France; Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.
Purpose: Urinary toxicity following radical prostatectomy (RP) and postoperative radiotherapy (RT) includes urinary incontinence and vesicourethral anastomosis (VUA) strictures. With the increasing use of stereotactic body radiotherapy (SBRT), dose-escalation, and reirradiation within the prostate bed (PB), standardization of the definition of urinary organs at risk (OARs) in the post-RP setting is needed. This works aims to provide a comprehensive review of the anatomical and physiopathological changes occurring after RP, as well as to provide a consensus on urinary OARs delineation for prostate cancer (PCa) EBRT in the post-RP setting.
View Article and Find Full Text PDFScand J Urol
September 2025
Boston Scientific Corporation, Marlborough, MA, USA.
Objectives: This capacity and budget impact analysis considers implications of offering a more diversified benign prostate enlargement (BPE) surgical care offering from a healthcare payer perspective in Sweden, Denmark, Norway and Finland.
Methods: A cohort simulation model compares 4-year treatment costs and capacity impact, including hospital bed-days and operating time, with Transurethral Resection of the Prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP) using MOSES™Technology, photoselective vaporisation of the prostate (PVP) and Rezūm™ Water Vapour Therapy (WVTT). Current treatment choice is compared to a hypothetical scenario, where TURP-proportion is reduced to 50% and volumes of HoLEP, PVP and WVTT are increased.
Front Immunol
August 2025
Department of Radiation Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Background And Purpose: This study aimed to compare the safety and efficacy of high-dose biologically effective dose (BED) versus standard dose regimens in stereotactic body radiotherapy (SBRT) for localized prostate cancer (PCa) using a propensity score matching (PSM) analysis.
Methods: Between June 2012 and February 2022, prostate-localized SBRT patients from two institutions were retrospectively reviewed. The high-dose group (n=12) received high-dose BED (>250Gy), and the control group (n=119) according to NCCN guidelines (35-37.
Phys Med
August 2025
Institut de cancérologie de l'Ouest, Saint-Herblain, France; CRCI2NA, INSERM UMR1307, CNRS-ERL6075, Université d'Angers, Université de Nantes, Nantes, France. Electronic address:
Background: Internal vectorised therapies, particularly with [177Lu]-labelled agents, are increasingly used for metastatic prostate cancer and neuroendocrine tumours. However, routine dosimetry for organs-at-risk and tumours remains limited due to the complexity and time requirements of current protocols.
Method: We developed a Generative Adversarial Network (GAN) to transform rapid 6 s SPECT projections into synthetic 30 s-equivalent projections.
Eur Urol Open Sci
September 2025
Department of Urology, the First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Background And Objective: Refractory bladder neck contracture (BNC) poses significant challenges after transurethral resection of the prostate. This study compares laparoscopic bladder neck wedge resection with posterior urethral bed preservation (LCBNRE) versus transurethral resection of the bladder neck (TURBN) in managing refractory BNC.
Methods: A retrospective analysis was conducted of 103 patients (2018-2023) divided into the LCBNRE ( = 58) and TURBN ( = 45) groups.